These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 26231201)

  • 1. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
    Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
    Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
    Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
    Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
    Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
    Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
    Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cereblon -  a new target of therapy in the treatment of multiple myeloma].
    Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
    Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
    Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
    Sievers QL; Gasser JA; Cowley GS; Fischer ES; Ebert BL
    Blood; 2018 Sep; 132(12):1293-1303. PubMed ID: 30042095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
    Zhu YX; Kortuem KM; Stewart AK
    Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
    Tao J; Yang J; Xu G
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
    Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
    Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.